person · Reporting owner

WALSH MATTHEW M

Disclosed activity across 5 companies

Tapewire entity: 46859
SEC CIK: 0001269428

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Catalent, Inc.CTLT · Entity 16279	EVP & Chief Financial Officer	August 24, 2017	August 28, 2017
Certara, Inc.CERT · Entity 787	Director	May 14, 2026	May 15, 2026
MULTI COLOR CorpLABL · Entity 156212	Director	October 03, 2016	October 05, 2016
Organon & Co.OGN · Entity 4115	Chief Financial Officer	March 31, 2026	April 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Catalent, Inc.

Report date August 24, 2017 · Filed August 28, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	103,703	Last balance in matching sequence After 2017-08-24 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2017-08-24 · Grant · Acquired 16,191 · Balance 111,948 F1: Received upon the achievement of the fiscal 2015-17 performance-based vesting criteria set forth in certain performance share units held by the reporting person. F2: Includes restricted stock units. Row 2 · 2017-08-24 · Tax withholding · Disposed 8,245 · Balance 103,703 F2: Includes restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Received upon the achievement of the fiscal 2015-17 performance-based vesting criteria set forth in certain performance share units held by the reporting person.

F2: Includes restricted stock units.

Certara, Inc.

Report date May 14, 2026 · Filed May 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	213,316	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Exercise / conversion · Acquired 15,757 · Balance 213,316 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-14 · Exercise / conversion · Disposed 15,757 · Balance 0 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	33,222	Reported balance After 2026-05-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-14 · Grant · Acquired 33,222 · Balance 33,222 F2: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

F2: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

MULTI COLOR Corp

Report date October 03, 2016 · Filed October 05, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,854	Reported balance After 2016-10-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2016-10-03 · Grant · Acquired 994 · Balance 1,854 F1: Restricted stock granted pursuant to Multi-Color's 2012 Stock Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock granted pursuant to Multi-Color's 2012 Stock Incentive Plan.

Organon & Co.

Report date March 31, 2026 · Filed April 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	212,746	Ending reported balance After 2026-03-31 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-03-31 · Exercise / conversion · Acquired 12,047 · Balance 202,707 Row 2 · 2026-03-31 · Tax withholding · Disposed 4,127 · Balance 198,580 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 21,546 · Balance 220,126 Row 4 · 2026-03-31 · Tax withholding · Disposed 7,380 · Balance 212,746 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	321,368	Reported balance After 2026-03-31 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-03-31 · Grant · Acquired 321,368 · Balance 321,368 F2: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	83,472	Reported balance After 2026-03-31 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-03-31 · Grant · Acquired 83,472 · Balance 83,472 F3: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-03-31 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-03-31 · Exercise / conversion · Disposed 12,047 · Balance 0 F4: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	43,094	Reported balance After 2026-03-31 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-03-31 · Exercise / conversion · Disposed 21,546 · Balance 43,094 F4: Each RSU represents a contingent right to receive one share of Organon common stock. F6: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Filing footnotes · ownership attribution and instrument terms

F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

F2: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

F3: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

F4: Each RSU represents a contingent right to receive one share of Organon common stock.

F5: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

F6: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Allergan plc

Report date May 08, 2020 · Filed May 12, 2020

Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	Direct	Reported balance After 2020-05-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-05-08 · Disposition to issuer · Disposed 12,039 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-05-08 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2020-05-08 · Disposition to issuer · Disposed 27,618 · Balance 0 F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-05-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-05-08 · Disposition to issuer · Disposed 28,021 · Balance 0 F3: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.

F3: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 31, 2024 Filed Apr 3, 2024 22:42 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	7,753	$0.00	$0.00	Disclosure SEC source: 0001821825-24-000049 · wk-form4_1712184118.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 29, 2024 Filed Apr 2, 2024 20:12 UTC	Organon & Co. OGN · Entity 4115	GrantStock Option (right to buy) · Derivative	185,185	$0.00 Strike: $18.80	$0.00	Disclosure SEC source: 0001821825-24-000018 · wk-form4_1712088709.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,185 Underlying: Common Stock · 185,185 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document
March 29, 2024 Filed Apr 2, 2024 20:12 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	45,212	$0.00	$0.00	Disclosure SEC source: 0001821825-24-000018 · wk-form4_1712088709.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,212 Underlying: Common Stock · 45,212 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document
February 28, 2024 Filed Mar 1, 2024 21:24 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	33,044	$0.00	$0.00	Disclosure SEC source: 0001821825-24-000011 · wk-form4_1709328243.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,044 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document
February 28, 2024 Filed Mar 1, 2024 21:24 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	11,393	$18.04	$205,529.72	Disclosure SEC source: 0001821825-24-000011 · wk-form4_1709328243.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,062 Read SEC document
February 28, 2024 Filed Mar 1, 2024 21:24 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	33,044	Not disclosed	Not disclosed	Disclosure SEC source: 0001821825-24-000011 · wk-form4_1709328243.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document
August 05, 2023 Filed Aug 8, 2023 22:07 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	22,347	$0.00	$0.00	Disclosure SEC source: 0001209191-23-045067 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,347 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of August 5, 2021, August 5, 2022 and August 5, 2023, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of August 5, 2021, August 5, 2022 and August 5, 2023, one-third of the RSUs vested. Read SEC document
August 05, 2023 Filed Aug 8, 2023 22:07 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	11,006	$21.53	$236,959.18	Disclosure SEC source: 0001209191-23-045067 · doc4.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,411 Read SEC document
August 05, 2023 Filed Aug 8, 2023 22:07 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	22,347	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045067 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document
May 23, 2023 Filed May 25, 2023 12:48 UTC	Certara, Inc. CERT · Entity 787	GrantRestricted Stock Units · Derivative	8,663	$0.00	$0.00	Disclosure SEC source: 0001415889-23-008752 · form4-05252023_120506.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,663 Underlying: Common Stock · 8,663 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted on May 23, 2023, under the Certara Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted on May 23, 2023, under the Certara Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted on May 23, 2023, under the Certara Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting. Read SEC document
May 17, 2023 Filed May 19, 2023 12:36 UTC	Certara, Inc. CERT · Entity 787	Exercise / conversionRestricted Stock Units · Derivative	9,067	$0.00	$0.00	Disclosure SEC source: 0001415889-23-008306 · form4-05192023_120517.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,067 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted under the Certara, Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs vested and were converted into common shares on the one-year anniversary of the date of grant. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted under the Certara, Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs vested and were converted into common shares on the one-year anniversary of the date of grant. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted under the Certara, Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs vested and were converted into common shares on the one-year anniversary of the date of grant. Read SEC document
May 17, 2023 Filed May 19, 2023 12:36 UTC	Certara, Inc. CERT · Entity 787	Exercise / conversionCommon Stock	9,067	$0.00	$0.00	Disclosure SEC source: 0001415889-23-008306 · form4-05192023_120517.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents restricted stock units ("RSUs") granted under the Certara, Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs vested and were converted into common shares on the one-year anniversary of the date of grant. Read SEC document
May 04, 2023 Filed May 8, 2023 22:46 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	8,310	$0.00	$0.00	Disclosure SEC source: 0001209191-23-028105 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,310 Underlying: Common Stock · 8,310 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document
May 04, 2023 Filed May 8, 2023 22:46 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	4,043	$24.24	$98,002.32	Disclosure SEC source: 0001209191-23-028105 · doc4.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,070 Read SEC document
May 04, 2023 Filed May 8, 2023 22:46 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	8,310	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-028105 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document
March 31, 2023 Filed Apr 5, 2023 00:21 UTC	Organon & Co. OGN · Entity 4115	GrantStock Option (right to buy) · Derivative	129,770	$0.00 Strike: $23.52	$0.00	Disclosure SEC source: 0001209191-23-023087 · doc4.xml · derivative · entry 5 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,770 Underlying: Common Stock · 129,770 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document
March 31, 2023 Filed Apr 5, 2023 00:21 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	36,139	$0.00	$0.00	Disclosure SEC source: 0001209191-23-023087 · doc4.xml · derivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,139 Underlying: Common Stock · 36,139 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document
March 31, 2023 Filed Apr 5, 2023 00:21 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	7,753	$0.00	$0.00	Disclosure SEC source: 0001209191-23-023087 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,507 Underlying: Common Stock · 7,753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document
March 31, 2023 Filed Apr 5, 2023 00:21 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	2,656	$23.09	$61,327.04	Disclosure SEC source: 0001209191-23-023087 · doc4.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,803 Read SEC document
March 31, 2023 Filed Apr 5, 2023 00:21 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	7,753	$0.00	$0.00	Disclosure SEC source: 0001209191-23-023087 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 14, 2022 Filed Nov 15, 2022 21:50 UTC	Certara, Inc. CERT · Entity 787	SaleCommon Stock	12,059	$14.74	$177,749.66	Disclosure SEC source: 0001415889-22-011400 · form4-11152022_091148.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,901 F1 · price: This transaction was executed in multiple trades at prices ranging from $14.66 to $14.88. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
August 05, 2022 Filed Aug 9, 2022 23:52 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	22,343	$0.00	$0.00	Disclosure SEC source: 0001104659-22-088173 · tm2222874-1_4seq1.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,343 Underlying: Common Stock · 22,343 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · shares: The total amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3 · derivative.exercise_date: On each of August 5, 2021 and August 5, 2022, one-third of the RSUs vested with the remaining RSUs to vest in one final installment on August 5, 2023. F3 · derivative.expiration_date: On each of August 5, 2021 and August 5, 2022, one-third of the RSUs vested with the remaining RSUs to vest in one final installment on August 5, 2023. Read SEC document
August 05, 2022 Filed Aug 9, 2022 23:52 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	10,790	$32.41	$349,703.90	Disclosure SEC source: 0001104659-22-088173 · tm2222874-1_4seq1.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,706 Read SEC document
August 05, 2022 Filed Aug 9, 2022 23:52 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	22,343	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-088173 · tm2222874-1_4seq1.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document
May 17, 2022 Filed May 18, 2022 20:42 UTC	Certara, Inc. CERT · Entity 787	GrantRestricted Stock Units · Derivative	9,067	$0.00	$0.00	Disclosure SEC source: 0001415889-22-005247 · form4-05182022_010541.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,067 Underlying: Common Stock · 9,067 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. F3 · shares: Represents 9,067 RSUs granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual shareholder meeting. The reporting person has reported prior awards of RSUs in Table 1 of Form 4. F4 · derivative.exercise_date: The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual shareholder meeting. F4 · derivative.expiration_date: The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual shareholder meeting. Read SEC document
May 04, 2022 Filed May 6, 2022 00:53 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	8,310	$0.00	$0.00	Disclosure SEC source: 0001104659-22-056635 · tm2214603-10_4seq1.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,310 Underlying: Common Stock · 8,310 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. F2 · derivative.expiration_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. Read SEC document
May 04, 2022 Filed May 6, 2022 00:53 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	2,847	$32.44	$92,356.68	Disclosure SEC source: 0001104659-22-056635 · tm2214603-10_4seq1.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,153 Read SEC document
May 04, 2022 Filed May 6, 2022 00:53 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	8,310	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-056635 · tm2214603-10_4seq1.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document
March 31, 2022 Filed Apr 4, 2022 22:11 UTC	Organon & Co. OGN · Entity 4115	GrantStock Option (right to buy) · Derivative	71,649	$0.00 Strike: $34.93	$0.00	Disclosure SEC source: 0001104659-22-042363 · tm2211465-8_4seq1.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,649 Underlying: Common Stock · 71,649 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document
March 31, 2022 Filed Apr 4, 2022 22:11 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	23,260	$0.00	$0.00	Disclosure SEC source: 0001104659-22-042363 · tm2211465-8_4seq1.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,260 Underlying: Common Stock · 23,260 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document
August 17, 2021 Filed Aug 19, 2021 21:08 UTC	Organon & Co. OGN · Entity 4115	GrantStock Option (Right to Buy) · Derivative	44,642	$0.00 Strike: $35.38	$0.00	Disclosure SEC source: 0000899243-21-033670 · doc4.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,642 Underlying: Common Stock · 44,642 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:44 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	22,343	$0.00	$0.00	Disclosure SEC source: 0000899243-21-032176 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,690 Underlying: Common Stock · 22,343 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:44 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	7,653	$28.63	$219,105.39	Disclosure SEC source: 0000899243-21-032176 · doc4.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,690 Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:44 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	22,343	$28.63	$639,680.09	Disclosure SEC source: 0000899243-21-032176 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 02, 2021 Filed Jun 5, 2021 01:16 UTC	Organon & Co. OGN · Entity 4115	GrantStock Option (Right to Buy) · Derivative	193,302	$0.00 Strike: $36.11	$0.00	Disclosure SEC source: 0000899243-21-022182 · doc4.xml · derivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,302 Underlying: Common Stock · 193,302 shares Expires 2031-05-03 F7 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document
June 02, 2021 Filed Jun 5, 2021 01:16 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	33,044	$0.00	$0.00	Disclosure SEC source: 0000899243-21-022182 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,044 Underlying: Common Stock · 33,044 shares Expires 2023-12-31 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F5 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023. Read SEC document
June 02, 2021 Filed Jun 5, 2021 01:16 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	24,930	$0.00	$0.00	Disclosure SEC source: 0000899243-21-022182 · doc4.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,930 Underlying: Common Stock · 24,930 shares Expires 2024-05-04 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document
June 02, 2021 Filed Jun 5, 2021 01:16 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	67,033	$0.00	$0.00	Disclosure SEC source: 0000899243-21-022182 · doc4.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,033 Underlying: Common Stock · 67,033 shares Expires 2023-08-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document
May 18, 2021 Filed May 18, 2021 20:52 UTC	Certara, Inc. CERT · Entity 787	GrantCommon Stock	7,059	$0.00	$0.00	Disclosure SEC source: 0001104659-21-068896 · tm2116784-4_4seq1.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,960 F1 · kind: Represents 7,059 restricted stock units ("RSU") granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual stockholder meeting. Read SEC document
December 15, 2020 Filed Dec 16, 2020 23:58 UTC	Certara, Inc. CERT · Entity 787	PurchaseCommon Stock	5,000	$23.00	$115,000.00	Disclosure SEC source: 0001104659-20-136447 · tm2038646-2_4seq1.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,901 F3 · kind: Shares were acquired in a directed share program in connection with the Issuer's initial public offering. Read SEC document
December 10, 2020 Filed Dec 16, 2020 23:58 UTC	Certara, Inc. CERT · Entity 787	GrantCommon Stock	145,597	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-136447 · tm2038646-2_4seq1.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,901 F2 · kind: Represents restricted stock previously granted to the reporting person on December 10, 2020. These shares of restricted stock were already reflected on the reporting person's previously filed Form 3. F2 · price: Represents restricted stock previously granted to the reporting person on December 10, 2020. These shares of restricted stock were already reflected on the reporting person's previously filed Form 3. Read SEC document
December 10, 2020 Filed Dec 16, 2020 23:58 UTC	Certara, Inc. CERT · Entity 787	OtherCommon Stock	22,304	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-136447 · tm2038646-2_4seq1.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,304 F1 · kind: Represents the receipt of shares of common stock of the Issuer from EQT Avatar Parent L.P. in exchange for units in EQT Avatar Parent L.P. previously held by the reporting person. These shares of common stock were already reflected on the reporting person's previously filed Form 3. F1 · price: Represents the receipt of shares of common stock of the Issuer from EQT Avatar Parent L.P. in exchange for units in EQT Avatar Parent L.P. previously held by the reporting person. These shares of common stock were already reflected on the reporting person's previously filed Form 3. Read SEC document
May 08, 2020 Filed May 12, 2020 01:44 UTC	Allergan plc AGN · Entity 149298	Disposition to issuerPerformance Stock Units · Derivative	28,021	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-012747 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 28,021 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F3 · price: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F3 · derivative.exercise_date: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F3 · derivative.expiration_date: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). Read SEC document
May 08, 2020 Filed May 12, 2020 01:44 UTC	Allergan plc AGN · Entity 149298	Disposition to issuerRestricted Stock Units	27,618	$0.00	$0.00	Disclosure SEC source: 0000899243-20-012747 · doc4.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · balance_after: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement. Read SEC document
May 08, 2020 Filed May 12, 2020 01:44 UTC	Allergan plc AGN · Entity 149298	Disposition to issuerOrdinary Shares, par value $0.0001	12,039	$0.00	$0.00	Disclosure SEC source: 0000899243-20-012747 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. Read SEC document
March 02, 2020 Filed Mar 4, 2020 19:17 UTC	Allergan plc AGN · Entity 149298	GrantOrdinary Shares, Par value $0.0001	15,476	$193.84	$2,999,867.84	Disclosure SEC source: 0001179110-20-003039 · edgar.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,657 F1 · balance_after: Includes restricted stock units issued pursuant to the Amended and Restated Allergan, Inc. 2011 Incentive Award Plan. Read SEC document
February 20, 2019 Filed Feb 21, 2019 22:41 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, Par value $0.0001	2,235	$140.33	$313,637.55	Disclosure SEC source: 0001179110-19-002262 · edgar.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,181 F1 · balance_after: Includes restricted stock units issued pursuant to the Amended and Restated Allergan, Inc. 2011 Incentive Award Plan. Read SEC document
November 16, 2018 Filed Nov 20, 2018 00:22 UTC	Allergan plc AGN · Entity 149298	PurchaseOrdinary Shares, Par value $0.0001	1,000	$157.00	$157,000.00	Disclosure SEC source: 0000903423-18-000616 · walsh4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,416 F1 · balance_after: Includes restricted shares issued pursuant to the Amended and Restated Allergan, Inc. 2011 Incentive Award Plan. Read SEC document
March 08, 2018 Filed Mar 8, 2018 15:44 UTC	Allergan plc AGN · Entity 149298	PurchaseOrdinary Shares, par value $0.0001	1,000	$153.96	$153,960.00	Disclosure SEC source: 0001179110-18-003831 · edgar.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,416 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
February 21, 2018 Filed Feb 22, 2018 21:25 UTC	Allergan plc AGN · Entity 149298	PurchaseOrdinary Shares, par value $0.0001	2,000	$160.94	$321,880.00	Disclosure SEC source: 0001179110-18-002591 · edgar.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,416 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.80 to $160.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.